Clinical study on TACE combined with PD-1 inhibitor and DC-CIK in the treatment of advanced liver cancer
Objective To analyze the clinical effect of transhepatic arterial chemoembolization(TACE)combined with programmed death receptor 1(PD-1)inhibitors and dendritic cell(DC)-cytokine induced killer cell(CIK)on advanced hepatocellular carcinoma.Methods A total of 92 patients with advanced hepatocellular carcinoma who were admitted to Hai'an Clinical College,Medical collgeg of Yangzhou University from May 2019 to March 2022 were prospectively selected and divided into study group(n=46)and control group(n=46)according to random number table method.TACE and DC-CIK treatment were given in both groups,and PD-1 inhibitor was additionally used in the study group.The duration of treatment was 3 months.The disease control rate(DCR),fibroblast growth factor(FGF),carcinoembryonic antigen(CEA),alpha fetoprotein(AFP),CD3+,CD4+,CD8+,the quality of life questionnaire-core 30(QLQ-C30)score and adverse reactions were compared between the two groups.Results The DCR of the study group was higher than that of the control group(71.74%vs.50.00%,P＜0.05).After treatment,the levels of FGF,CEA,AFP and CD8+were decreased in both groups,while CD3+and CD4+levels and QLQ-C30 score were increased(P＜0.05).After treatment,the levels of FGF,CEA,AFP and CD8+in the study group were significantly lower than those in the control group,and CD3+and CD4+levels and QLQ-C30 score in the study group were significantly higher than those in the control group(P＜0.05).There were no significant differences in the incidences of grade Ⅰ-Ⅳ hypothyroidism,hypertension,hand foot syndrome or rash between the two groups(P＞0.05).Conclusion TACE combined with PD-1 inhibitor and DC-CIK is effective,safe and reliable in the treatment of advanced liver cancer.It can reduce the levels of FGF,CEA and AFP,improving immune function and quality of life of the patients.
万方数据
维普
